Abbott Laboratories v. Gardner
|Abbott Laboratories v. Gardner
|case heard before the United States Supreme Court. Abbott Laboratories held that drug companies were not prohibited by the ripeness doctrine from challenging a U.S. Food and Drug Administration (FDA) regulation requiring a prescription drug's generic name to appear on all related printed materials. The government argued that the case was not ripe because the regulation had yet to be enforced; however, that argument failed where prosecution was likely and there was substantial hardship to denying a pre-enforcement challenge to the statute. — Excerpted from Abbott Laboratories v. Gardner on Wikipedia, the free encyclopedia.Abbott Laboratories v. Gardner, , was a|
United States Supreme Court
ABBOTT LABORATORIES v. GARDNER
Argued: Jan. 16, 1967. --- Decided: May 22, 1967
Gerhard A. Gesell, Washington, D.C., for petitioners.
Nathan Lewin, Washington, D.C., for respondents.
Mr. Justice HARLAN delivered the opinion of the Court.
|This work is in the public domain in the United States because it is a work of the United States federal government (see 17 U.S.C. 105).|